19th September 2026

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA
ISIN: INE0XJ501010

Sub: Proceedings of the Annual General Meeting held on 19th September, 2026

Dear Sir,

Pursuant to provisions of Clause A (13) of Part A of Schedule III of Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 please find enclosed herewith the proceedings of 3rd Annual General Meeting of the members of the Company held on 19th September, 2026 at 01.00 pm through Video Conferencing / Other Audio-Visual Means (VC).

Thanking You

Yours Faithfully,
For Invicta Diagnostic Limited

Sanket Vinod Jain

Digitally signed by Sanket Vinod Jain
Date: 2026.09.19 19:04:21 +05'30'

Sanket Vinod Jain
Chairman and Managing Director
DIN: 08299039
Place: Mumbai

Proceedings of the Annual General Meeting held on 19th September, 2026

3rd Annual General Meeting of the members of the Company held on 19th September, 2026 at 01.00 pm through Video Conferencing / Other Audio-Visual Means (VC).

The Company Secretary welcomed the Shareholders at the 3rd Annual General Meeting of the members of the Company. Mr. Sanket Vinod Jain, Chairman chaired the meeting.

Total 16 Shareholders attended the AGM.

The Company Secretary introduced the members of the Board and acknowledged the attendance of all Directors, KPM's, Auditor and Scrutinizer of the Company.

At 1:00 p.m., the requisite quorum was present. However, the Chairman decided to wait for a further two to three minutes to allow any other Members who may wish to join the meeting to do so. Thereafter, upon ascertaining that the requisite quorum was present, the meeting was formally commenced at 1:04 p.m.

The Chairman and CFO thereafter addressed the shareholders and their speech is enclosed as Annexure 1.

Ms. Soniya Mahajan, Company Secretary & Compliance officer of the company thereafter read the agenda items for consideration and approval.

Following items of business as stated in the notice of 3rd Annual General Meeting were taken up for consideration:

Sr. No.	Agenda	Type of Business	Type of Resolution
1	To consider and adopt (a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors and Auditors thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 and the report of Auditors thereon	Ordinary Business	Ordinary Resolution
2	To appoint a director in place of Mr. Ketan Jayantilal Jain (DIN: 07819226), who retires by rotation and, being eligible, seeks re-appointment	Ordinary Business	Ordinary Resolution
3	Appointment of M/s Shrenik Nagaonkar & Associates, Company Secretaries as Secretarial Auditor of the Company	Special Business	Ordinary Resolution
4	Appointment of Mr. Sanket Vinod Jain (DIN: 08299039) as Managing Director of the Company	Special Business	Ordinary Resolution

Company Secretary thereafter gave vote of thanks and informed shareholders that the Scrutiniser will consolidate the results and submit the report within 48 hours from the conclusion of AGM. The results will be uploaded on the Company's website and the NSE portal.

The meeting was concluded at 1.21 pm
Thanking You

Yours Faithfully,
For Invicta Diagnostic Limited

Sanket Vinod Jain
Digitally signed by Sanket Vinod Jain
Date: 2026.09.19 19:04:44 +05'30'

Sanket Vinod Jain
Chairman and Managing Director
DIN: 08299039
Place: Mumbai

3rd Annual General Meeting of Invicta Diagnostic Limited

A. Speech of Mr. Sanket Jain, Chairman and Managing Director

Dear Members,

A very warm welcome to all of you to the 3rd Annual General Meeting of Invicta Diagnostic Limited. On behalf of the Board and the entire Invicta family, I sincerely thank you for your continued trust, confidence and support.

FY 2025–26 was an important year for the Company, marked by the successful completion of our IPO and listing on the NSE Emerge platform. The Company raised approximately ₹28.12 crore through the fresh issue, which has strengthened our capital base and also increased our responsibility towards transparency, governance and long-term value creation.

During the year, we commenced operations at our Dadar centre and subsequently expanded into Pune, Nashik and Shegaon. With these additions, our network has grown to 11 diagnostic centres and 2 centralised laboratories. We remain focused on expanding our presence across Maharashtra while improving the utilisation and efficiency of our existing infrastructure.

As part of our disciplined growth strategy, the Company also diversified the utilisation of a portion of its IPO proceeds and subsequently acquired a 51% stake in Vinchurkar Diagnostics Private Limited in May 2026, making it a subsidiary. We believe this acquisition will complement our expansion strategy and strengthen our presence in Maharashtra.

Going forward, our focus will remain on quality healthcare, better utilisation of our infrastructure, technology adoption, patient-centric services, selective expansion and disciplined capital allocation. As a listed company, we remain firmly committed to transparency, accountability and sustainable long-term value creation.

I sincerely thank our shareholders, Board members, doctors, employees, auditors, bankers, advisors, business partners and healthcare professionals for their valuable contribution. Most importantly, I thank our patients and healthcare partners for their continued trust in us.

We have entered a new chapter in our journey, and with your continued support, we look forward to building a stronger, more integrated and sustainable diagnostic healthcare platform.

Thank you.

B. Speech of Mr. Rohit Srivastava, CFO

Respected Chairman, Members of the Board and Esteemed Shareholders,

Good afternoon to everyone.

I am pleased to present the key financial highlights of Invicta Diagnostic Limited for the financial year ended March 31, 2026.

FY 2025–26 was an important year for the Company, marked by growth in our operations, successful completion of the IPO and strengthening of our financial position.

On a standalone basis, the Company recorded total income of Rs. 2,140.91 Lakhs as against Rs. 1,773.42Lakhs in the previous year. The Company earned Profit Before Tax of Rs. 725.41 Lakhs and Profit After Tax of Rs.552.81 Lakhs during the year under review, as compared to Profit Before Tax of Rs. 668.39 Lakhs and Profit After Tax of Rs. 522.74 Lakhs, respectively, in the previous year.

On a consolidated basis, Company generated consolidated total income of Rs. 3,304.19 Lakhs as against Rs. 3018.14 Lakhs in the previous year. The Company earned Consolidated Profit Before Tax of Rs. 700.84 Lakhs and Consolidated Profit After Tax of Rs. 487.32 Lakhs during the year under review, as compared to Consolidated Profit Before Tax of Rs. 656.36 Lakhs and Consolidated Profit After Tax of Rs. 492.95 Lakhs, respectively, in the previous year.

During the year, the Company also commenced operations at its Dadar centre, followed by expansion into Pune, Nashik and Shegaon after the year-end. The Company now has 11 diagnostic centres and 2 centralised laboratories. Our immediate focus is on ramping up these centres, improving utilisation and enhancing operational efficiency.

Going forward, our financial priorities will remain focused on revenue growth, profitability, efficient utilisation of capital, working capital management and disciplined capital allocation. We will continue to invest selectively in infrastructure, technology and advanced diagnostic capabilities while maintaining strong financial controls and governance.

Based on our current business plans and management expectations, we are targeting consolidated revenue in the range of approximately ₹45 to ₹50 crore, with an EBITDA margin of around 25%.

I would like to clarify that these figures represent the management's current indicative business targets and outlook and should not be construed as a guarantee, assurance or forecast of future financial performance. Actual results may vary depending on business performance, patient volumes, market conditions, economic factors, regulatory developments and other risks and uncertainties.

Our objective remains to achieve profitable and sustainable growth while continuing to strengthen the Company's fundamentals and deliver long-term value to all our stakeholders.

To conclude, FY 2025–26 has laid a strong foundation for the Company's next phase of growth. Our focus now is to convert our expanded platform and strengthened capital base into sustainable and profitable operating performance.

I sincerely thank our shareholders, Board, management, employees, auditors, bankers, advisors and all other stakeholders for their continued support and confidence.

Thank you, and I wish the Company and all its shareholders continued success.